NASDAQ:ACOR - Acorda Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.00
  • Forecasted Upside: 259.41 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
▲ +0.92 (24.15%)

This chart shows the closing price for ACOR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Acorda Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ACOR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ACOR

Analyst Price Target is $17.00
▲ +259.41% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Acorda Therapeutics in the last 3 months. The average price target is $17.00, with a high forecast of $35.00 and a low forecast of $6.00. The average price target represents a 259.41% upside from the last price of $4.73.

This chart shows the closing price for ACOR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Acorda Therapeutics. This rating has held steady since May 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 3 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/17/2021HC WainwrightUpgradeNeutral ➝ Buy$5.00 ➝ $10.00High
1/13/2021CowenBoost Price Target$5.00 ➝ $35.00High
8/11/2020Jefferies Financial GroupReiterated RatingHold$6.00Low
5/6/2020HC WainwrightReiterated RatingNeutral$36.00 ➝ $30.00High
3/9/2020HC WainwrightReiterated RatingHold$36.00High
2/16/2020JPMorgan Chase & Co.Reiterated RatingSellHigh
1/21/2020HC WainwrightReiterated RatingHold$30.00Medium
1/16/2020CowenReiterated RatingBuy$60.00Medium
12/30/2019HC WainwrightReiterated RatingHold$36.00High
12/23/2019HC WainwrightReiterated RatingHold$36.00N/A
11/5/2019HC WainwrightReiterated RatingHold$36.00High
10/24/2019JPMorgan Chase & Co.DowngradeNeutral ➝ Underweight$8.40High
8/14/2019HC WainwrightDowngradeBuy ➝ Neutral$186.00 ➝ $36.00High
8/2/2019JPMorgan Chase & Co.Set Price TargetHold$42.00Low
8/2/2019Stifel NicolausLower Price TargetHold$72.00 ➝ $42.00High
8/2/2019WedbushLower Price TargetNeutral$48.00 ➝ $42.00High
8/2/2019Cantor FitzgeraldLower Price TargetNeutral$120.00 ➝ $72.00High
5/22/2019WedbushInitiated CoverageNeutral ➝ Neutral$72.00High
5/7/2019JPMorgan Chase & Co.Reiterated RatingHold$108.00High
3/19/2019OppenheimerReiterated RatingHoldHigh
2/15/2019Cantor FitzgeraldReiterated RatingHold$120.00High
1/23/2019HC WainwrightSet Price TargetBuy$198.00Low
1/14/2019HC WainwrightSet Price TargetBuy$198.00Low
1/7/2019CowenReiterated RatingBuy$180.00Medium
1/4/2019HC WainwrightReiterated RatingBuy$198.00High
1/2/2019OppenheimerSet Price TargetHold$108.00High
1/2/2019Cantor FitzgeraldSet Price TargetHold$192.00High
1/2/2019JPMorgan Chase & Co.Reiterated RatingHoldHigh
12/26/2018Raymond JamesReiterated RatingSellMedium
12/26/2018JPMorgan Chase & Co.Reiterated RatingNeutral ➝ HoldHigh
12/24/2018OppenheimerSet Price TargetHold ACOR$108.00High
12/24/2018Cantor FitzgeraldSet Price TargetHold ACOR$192.00High
12/11/2018The Goldman Sachs GroupDowngradeNeutral ➝ Sell$114.00 ➝ $60.00High
11/5/2018HC WainwrightReiterated RatingBuy$180.00High
11/4/2018Jefferies Financial GroupReiterated RatingHold$132.00Medium
10/31/2018JPMorgan Chase & Co.Set Price TargetHold$108.00High
10/31/2018Cantor FitzgeraldSet Price TargetHold$192.00Low
10/24/2018HC WainwrightSet Price TargetBuy$168.00High
10/12/2018JPMorgan Chase & Co.Reiterated RatingHoldLow
10/5/2018Stifel NicolausLower Price TargetHold ➝ Hold$150.00 ➝ $114.00High
9/23/2018OppenheimerSet Price TargetHold$108.00High
9/17/2018HC WainwrightSet Price TargetBuy$168.00Low
9/12/2018OppenheimerSet Price TargetHold$126.00High
9/11/2018HC WainwrightSet Price TargetBuy$186.00High
9/10/2018Cantor FitzgeraldReiterated RatingHold$192.00High
9/10/2018JPMorgan Chase & Co.Set Price TargetHold$120.00Medium
8/23/2018Cantor FitzgeraldInitiated CoverageNeutral$192.00Medium
8/7/2018Stifel NicolausBoost Price TargetHold ➝ Hold$90.00 ➝ $150.00Low
8/6/2018HC WainwrightSet Price TargetBuy$186.00High
8/2/2018OppenheimerSet Price TargetHold$126.00Medium
8/2/2018CowenReiterated RatingBuy$180.00Medium
7/30/2018Cantor FitzgeraldSet Price TargetHold$102.00Low
7/26/2018HC WainwrightSet Price TargetBuy$186.00Low
7/25/2018OppenheimerSet Price TargetHold$126.00Low
7/25/2018JPMorgan Chase & Co.Reiterated RatingHoldLow
6/11/2018HC WainwrightSet Price TargetBuy$186.00High
6/11/2018OppenheimerSet Price TargetHold$126.00High
5/30/2018HC WainwrightSet Price TargetBuy$186.00High
5/3/2018HC WainwrightSet Price TargetBuy$186.00Low
5/2/2018OppenheimerSet Price TargetHold$126.00Low
5/2/2018CowenReiterated RatingBuy$180.00High
4/2/2018HC WainwrightReiterated RatingBuy$186.00High
3/21/2018OppenheimerReiterated RatingHoldHigh
2/16/2018OppenheimerSet Price TargetHold$126.00Low
2/15/2018Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$150.60 ➝ $222.00High
2/7/2018The Goldman Sachs GroupUpgradeSell ➝ NeutralLow
1/31/2018OppenheimerBoost Price TargetMarket Perform ➝ Market Perform$108.00 ➝ $126.00Medium
1/17/2018HC WainwrightReiterated RatingBuy ➝ Buy$204.00 ➝ $186.00Medium
1/9/2018JPMorgan Chase & Co.Reiterated RatingHoldLow
12/14/2017HC WainwrightSet Price TargetBuy$204.00Medium
11/28/2017Piper Jaffray CompaniesReiterated RatingNeutral$132.00Low
11/20/2017HC WainwrightSet Price TargetBuy$204.00N/A
11/17/2017CowenReiterated RatingBuy$180.00N/A
11/16/2017Janney Montgomery ScottSet Price TargetHold$156.00 ➝ $102.00N/A
11/16/2017Raymond JamesDowngradeMarket Perform ➝ Underperform$42.00 ➝ $78.00N/A
11/16/2017Stifel NicolausDowngradeBuy ➝ Hold$156.00 ➝ $90.00N/A
11/15/2017JPMorgan Chase & Co.Lower Price TargetNeutral$114.00N/A
11/15/2017SVB LeerinkLower Price TargetMarket Perform$108.00N/A
11/15/2017OppenheimerSet Price TargetHold$108.00N/A
11/15/2017Cantor FitzgeraldLower Price TargetNeutral$108.00 ➝ $96.00N/A
11/9/2017CIBCInitiated CoverageMarket Perform ➝ Market PerformN/A
11/9/2017OppenheimerInitiated CoverageMarket Perform$162.00N/A
11/8/2017HC WainwrightInitiated CoverageBuy$210.00N/A
11/1/2017Jefferies Financial GroupBoost Price TargetHold$132.00 ➝ $150.00N/A
10/31/2017JPMorgan Chase & Co.Set Price TargetHold$144.00N/A
10/31/2017Cantor FitzgeraldReiterated RatingHold$108.00N/A
10/6/2017The Goldman Sachs GroupReiterated RatingSell ➝ Sell$120.00N/A
9/28/2017Cantor FitzgeraldReiterated RatingHold$108.00Low
8/31/2017Stifel NicolausReiterated RatingBuy$180.00 ➝ $156.00Low
8/30/2017Janney Montgomery ScottReiterated RatingHold$108.00Low
8/29/2017CowenReiterated RatingBuy$210.00Low
8/29/2017Cantor FitzgeraldReiterated RatingHold$108.00Low
7/28/2017Stifel NicolausReiterated RatingBuyLow
7/10/2017Jefferies Financial GroupInitiated CoverageHold ➝ Hold$132.00Medium
6/7/2017CowenReiterated RatingOutperform$210.00Low
6/6/2017JPMorgan Chase & Co.Set Price TargetHold$144.00Low
4/3/2017CowenLower Price TargetOutperform$360.00 ➝ $210.00High
4/3/2017The Goldman Sachs GroupReiterated RatingNeutral$132.00High
4/3/2017JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$192.00 ➝ $144.00High
4/3/2017Janney Montgomery ScottDowngradeBuy ➝ Neutral$228.00 ➝ $114.00High
3/30/2017Stifel NicolausReiterated RatingBuy$180.00High
3/13/2017Janney Montgomery ScottUpgradeNeutral ➝ Buy$138.00 ➝ $228.00Low
2/15/2017Cantor FitzgeraldReiterated RatingNeutral ➝ PositiveN/A
2/15/2017The Goldman Sachs GroupUpgradeSell ➝ NeutralN/A
2/14/2017CowenSet Price TargetBuy$360.00N/A
2/14/2017Cantor FitzgeraldSet Price TargetHold$132.00N/A
2/9/2017JPMorgan Chase & Co.Set Price TargetBuy$192.00N/A
1/22/2017JPMorgan Chase & Co.Reiterated RatingBuy$192.00N/A
1/9/2017CowenReiterated RatingBuy$360.00N/A
1/9/2017Cantor FitzgeraldReiterated RatingHold$126.00N/A
1/8/2017Evercore ISISet Price TargetHold$138.00N/A
1/3/2017CowenSet Price TargetBuy$360.00N/A
12/21/2016Cantor FitzgeraldReiterated RatingNeutralN/A
12/19/2016Janney Montgomery ScottInitiated CoverageNeutral$138.00N/A
12/15/2016Cantor FitzgeraldInitiated CoverageNeutral$126.00N/A
11/30/2016JPMorgan Chase & Co.UpgradeNeutral ➝ OverweightN/A
11/23/2016SVB LeerinkReiterated RatingMarket PerformN/A
10/27/2016CowenReiterated RatingBuy$360.00N/A
10/4/2016SVB LeerinkInitiated CoverageMarket Perform$150.00N/A
8/25/2016Stifel NicolausReiterated RatingBuyN/A
8/25/2016JPMorgan Chase & Co.Reiterated RatingNeutralN/A
8/25/2016CowenReiterated RatingOutperform$390.00N/A
(Data available from 7/23/2016 forward)
Acorda Therapeutics logo
Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine) and Selincro (nalmefene). The firm's also offers Research and Development Programs like ARCUS for acute migraine, Cimaglermin alfa and rHIgM22. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.
Read More

Today's Range

Now: $4.73
Low: $4.42
High: $6.36

50 Day Range

MA: $4.18
Low: $3.61
High: $5.23

52 Week Range

Now: $4.73
Low: $2.53
High: $9.84


50,597,946 shs

Average Volume

948,441 shs

Market Capitalization

$44.88 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Acorda Therapeutics?

The following equities research analysts have issued reports on Acorda Therapeutics in the last twelve months: Cowen Inc, HC Wainwright, Jefferies Financial Group Inc., and Zacks Investment Research.
View the latest analyst ratings for ACOR.

What is the current price target for Acorda Therapeutics?

3 Wall Street analysts have set twelve-month price targets for Acorda Therapeutics in the last year. Their average twelve-month price target is $17.00, suggesting a possible upside of 237.3%. Cowen Inc has the highest price target set, predicting ACOR will reach $35.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $6.00 for Acorda Therapeutics in the next year.
View the latest price targets for ACOR.

What is the current consensus analyst rating for Acorda Therapeutics?

Acorda Therapeutics currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ACOR will outperform the market and that investors should add to their positions of Acorda Therapeutics.
View the latest ratings for ACOR.

What other companies compete with Acorda Therapeutics?

How do I contact Acorda Therapeutics' investor relations team?

Acorda Therapeutics' physical mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company's listed phone number is (914) 347-4300. The official website for Acorda Therapeutics is